Clinical Trials Directory

Trials / Completed

CompletedNCT02826291

SLNM in Endometrial Cancer Combined With OSNA

Sentinel Lymph Node Mapping in Endometrial Cancer Patients Combined With One-step Nucleic Acid Amplification (OSNA)

Status
Completed
Phase
Study type
Observational
Enrollment
58 (actual)
Sponsor
Charles University, Czech Republic · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

The aim of the study is to compare one-step nucleic acid amplification method (OSNA) with histological ultrastaging examination in the sentinel lymph node assessment in patients with endometrial cancer. The molecular biologic method OSNA is a modern way of metastatic spread detection in lymphatic nodes using quantitative reverse transcription polymerase chain reaction. Cytokeratin 19 (CK 19) was selected based on previous studies as the optimal mRNA marker (detected by OSNA). The intraoperative identification and rapid assessment of sentinel lymph nodes by OSNA could help to improve the standards of care in endometrial cancer patients.

Detailed description

Method: After the sentinel lymph node detection (ICG, 99m Tc or Bleu Patente) and sentinel node/nodes removal is performed, the node/nodes is/are cut in 2-mm slices parallel to short axis of the node. The odd-numbered blocks will be examined by the OSNA method and the even-numbered blocks will be examined by conventional histopathological methods including immunohistochemistry. Statistical analysis to identify differences will be performed subsequently.

Conditions

Interventions

TypeNameDescription
DEVICERD-100i, OSNAquantitative reverse transcription polymerase chain reaction (qRT-PCR) cytokeratin-19 detection in specimen (sentinel lymph node)

Timeline

Start date
2016-03-01
Primary completion
2018-01-31
Completion
2018-02-01
First posted
2016-07-07
Last updated
2018-07-18

Locations

1 site across 1 country: Czechia

Source: ClinicalTrials.gov record NCT02826291. Inclusion in this directory is not an endorsement.